What is Trulicity?

Trulicity is a brand of Dulaglutide. FDA has approved it for 3 uses. People take it once weekly, at any time of day, with or without food. The first labeled dose is 0.75 mg. The highest is 4.5 mg.

Source: Current FDA label, checked 2026-08-13

What matters first

Medicine: Dulaglutide
How often: Once weekly, at any time of day, with or without food
Starting dose: 0.75 mg
Highest labeled dose: 4.5 mg

Choose what you need

Go straight to the answer

DosageTrulicity dosage scheduleSee every labeled step from 0.75 mg to 4.5 mg.PriceWhat Trulicity costsCompare the list price, published cash offers and key limits.

Approved uses

What is Trulicity approved to treat?

Adults with type 2 diabetes, together with diet and exercise, to improve blood sugar.

Labeled maintenance: 0.75 mg once weekly, raised in steps to 4.5 mg where blood sugar needs more help

Children age 10 and older with type 2 diabetes, together with diet and exercise.

Labeled maintenance: 0.75 mg once weekly, raised once to 1.5 mg where blood sugar needs more help

Adults with type 2 diabetes and heart risk, to lower the risk of heart attack, stroke and heart-related death.

Labeled maintenance: The same step pattern the label sets for blood sugar

Not an approved use: The Trulicity label covers type 2 diabetes and nothing else. It sets no dose for weight, and Lilly never gave dulaglutide a second brand for weight the way it gave tirzepatide one. Drugs@FDA lists dulaglutide under one application and no others, and that application is a biologics license — which is a route with no generic at the end of it.

The product itself

How Trulicity comes

Single-dose pen

0.75, 1.5, 3 and 4.5 mg per 0.5 mL

1 dose, in a carton of 4

Eli Lilly and Company makes Trulicity under BLA 125469. The label says it is given as a shot under the skin.

6primary sources, each with the day we read it — open the documents used on this page

Trulicity (dulaglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-13FDA label
Trulicity (dulaglutide) Prescribing Information, revised 03/2026 — Drugs@FDA BLA 125469/S-065retrieved 2026-08-13FDA label
FDA licensing letter, BLA 125469 — Trulicity (dulaglutide), glycemic control in adults with type 2 diabetesretrieved 2026-08-13FDA label
FDA supplement approval letter, BLA 125469/S-051 — expansion of the Trulicity glycemic-control indication to pediatric patients 10 years of age and olderretrieved 2026-08-13FDA label
FDA supplement approval letter, BLA 125469/S-033 — Trulicity indication for reducing major adverse cardiovascular events in type 2 diabetes (REWIND)retrieved 2026-08-13FDA label
Drugs@FDA via openFDA — every application containing dulaglutide, which is BLA 125469 and nothing elseretrieved 2026-08-13FDA label

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer